Swixx BioPharma
Swixx BioPharma is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. With the comprehensive services to our partner companies, we are bridging the gap between pharmaceutical innovation and patient access. After 10 years of operations, our presence extends across 46 countries in Central and Eastern Europe, Eurasia/CIS*, Latin America, and MENAT**. Committed to enhancing patient outcomes, our dedicated team of over 1,600 employees tirelessly strives to provide access to modern medicines for those in need. Swixx BioPharma focuses on four strategic therapeutic areas: Rare Diseases, Oncology/Hematology, Specialty Care, and Vaccines.
* CIS:Commonwealth of Independent States
** MENAT: Middle East, North Africa, and Turkey
Swixx BioPharma holds a unique position in the pharmaceutical industry. Our operating model allows Swixx to be a versatile and knowledgeable partner, enabling us to build in-depth expertise across a wider range therapy areas than any single company. At Swixx, we operate with a culture of international companies, always striving to innovate.
In Cardiology, Swixx partners with several international companies supporting the treatment of patients with cardiovascular diseases across our markets. We are a proud partner of Bristol Myers Squibb, a company with a 70-year legacy of discovering and developing paradigm-changing medicines in cardiovascular care.
Explore more about us at www.swixxbiopharma.com